NLS Collaboration

Medivir has announced a clinical trial collaboration and supply agreement with Eisai to evaluate fostrox in combination with lenvatinib mesylate in a randomized, phase 2b study in second-line advanced liver cancer patients.

NEOGAP Therapeutics has entered a strategic collaboration with NorthX Biologics to advance manufacturing strategies for NEOGAP’s personalized cancer cell therapy.

Ascendis Pharma has granted Novo Nordisk an exclusive worldwide license to the TransCon technology platform to develop, manufacture and commercialize Novo Nordisk proprietary products in metabolic diseases (including obesity and type 2 diabetes) and a product-by-product exclusive license in cardiovascular diseases.

The capital of Sweden possesses not only world-renowned academic research and high profile life science companies, it is also home to many of the country’s most important national life science efforts and leading centers.

Cereno Scientific has signed an agreement with medical technology company Fluidda on Respiratory Imaging solutions, with the aim to visualize signs of reverse remodeling of lead drug candidate CS1 in Pulmonary Arterial Hypertension (PAH) in a clinical setting.

Evaxion Biotech has entered into an option and license agreement with MSD for two preclinical vaccine candidates.